本文選題：DPP-抑制劑 + 西格列汀��； 參考：《重慶醫(yī)學(xué)》2017年11期

【摘要】：目的探討DPP-4抑制劑西格列汀治療新診斷老年2型糖尿病的臨床療效及其對(duì)血壓、體質(zhì)量的影響。方法選取該院2013年7月至2015年6月收治的100例新診斷老年2型糖尿病患者作為研究對(duì)象,將其分為觀察組和對(duì)照組,每組50例。對(duì)照組在飲食控制及鍛煉的基礎(chǔ)上使用安慰劑進(jìn)行治療,觀察組在飲食控制及鍛煉基礎(chǔ)上使用西格列汀進(jìn)行治療。對(duì)比患者治療前后的空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化清蛋白(GA)的變化情況,監(jiān)測(cè)低血糖發(fā)生率、血壓、體質(zhì)量等變化及不良反應(yīng)。結(jié)果治療后,兩組患者的病情均明顯好轉(zhuǎn),且觀察組FPG、2hPG、GA的變化情況均顯著優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,兩組患者血壓、體質(zhì)量和BMI與治療前比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,觀察組與對(duì)照組不良反應(yīng)發(fā)生率分別為10.0%和8.0%,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論應(yīng)用DPP-4抑制劑西格列汀治療新診斷老年2型糖尿病患者臨床療效好。
[Abstract]:Objective to investigate the clinical efficacy of DPP-4 inhibitor siglitatin in the treatment of newly diagnosed type 2 diabetes mellitus and its effect on blood pressure and body mass. Methods from July 2013 to June 2015, 100 newly diagnosed elderly patients with type 2 diabetes mellitus were selected and divided into observation group and control group with 50 cases in each group. The control group was treated with placebo on the basis of diet control and exercise, while the observation group was treated with siglitatin on the basis of diet control and exercise. The changes of fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h) and glycosylated albumin (GAA) were compared before and after treatment. The incidence of hypoglycemia, blood pressure, body mass and adverse reactions were monitored. Results after treatment, the condition of patients in both groups was obviously improved, and the changes of PGGA in the observation group were significantly better than those in the control group, and the difference was statistically significant (P 0.05). After treatment, there was no significant difference in blood pressure, body mass and BMI between the two groups. After treatment, the incidence of adverse reactions in the observation group and the control group was 10.0% and 8.0%, respectively, with no significant difference (P 0.05). Conclusion DPP-4 inhibitor siglitatin is effective in the treatment of newly diagnosed elderly type 2 diabetes.
【作者單位】： 福建醫(yī)科大學(xué)附屬閩東醫(yī)院內(nèi)分泌科;福建醫(yī)科大學(xué)附屬閩東醫(yī)院眼科;
【基金】：寧德市科學(xué)技術(shù)計(jì)劃項(xiàng)目(20130144)
【分類號(hào)】：R587.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 賈雪冬;張俊;劉明亮;;五種上市DPP-4抑制劑的臨床藥動(dòng)學(xué)比較[J];國(guó)外醫(yī)藥(抗生素分冊(cè));2014年01期

2 李珊珊;張潔;肖珊;;沙格列汀治療初診伴超重或肥胖的2型糖尿病患者療效觀察[J];實(shí)用糖尿病雜志;2013年03期

3 占美;徐s，

本文編號(hào)：1842790